A 50-year-old woman presents to the clinic with joint pain that has persisted for the last 2 months. She reports having intermittently swollen, painful hands bilaterally. She adds that when she wakes up in the morning, her hands are stiff and do not loosen up until an hour later. The pain tends to improve with movement. Physical examination is significant for warm, swollen, tender proximal interphalangeal joints, metacarpophalangeal joints, and wrists bilaterally. Laboratory results are positive for rheumatoid factor (4-fold greater than the upper limit of normal (ULN)) and anti-cyclic citrullinated peptide (anti-CCP) antibodies (3-fold greater than ULN). CRP and ESR are elevated. Plain X-rays of the hand joints show periarticular osteopenia and bony erosions. She was started on the first-line drug for her condition which inhibits dihydrofolate reductase. Which medication was this patient started on?
Q302
A 78-year-old woman presents to the orthopedic department for an elective total left knee arthroplasty. She has had essential hypertension for 25 years and type 2 diabetes mellitus for 35 years. She has smoked 20–30 cigarettes per day for the past 40 years. The operation was uncomplicated. On day 3 post-surgery, she complains of left leg pain and swelling. On examination, her left leg appears red and edematous, and there are dilated superficial veins on the left foot. Using Wells’ criteria, the patient is diagnosed with a provoked deep venous thrombosis. Which of the following is the best initial therapy for this patient?
Q303
A 36-year-old man comes to the physician because of increasing back pain for the past 6 months. The pain is worse when he wakes up and improves throughout the day. He has problems bending forward. He has taken ibuprofen which resulted in limited relief. His only medication is a topical corticosteroid for two erythematous, itchy patches of the skin. His mother has rheumatoid arthritis. His temperature is 37.1°C (98.8°F), pulse is 75/min, respirations are 14/min, and blood pressure is 126/82 mmHg. Examination shows a limited spinal flexion. He has two patches with erythematous papules on his right forearm. He has tenderness on percussion of his sacroiliac joints. An x-ray of his spine is shown. Which of the following is most likely to improve mobility in this patient?
Q304
A previously healthy 46-year-old woman comes to the physician because of a 3-month history of fatigue and progressive shortness of breath. She does not take any medications. Her pulse is 93/min and blood pressure is 112/80 mm Hg. Examination shows no abnormalities. Her hemoglobin concentration is 8 g/dL, leukocyte count is 22,000/mm3, and platelet count is 80,000/mm3. A peripheral blood smear shows increased numbers of circulating myeloblasts. Bone marrow biopsy confirms the diagnosis of acute myeloid leukemia. ECG, x-ray of the chest, and echocardiogram show no abnormalities. The patient is scheduled to start induction chemotherapy with cytarabine and daunorubicin. This patient is at increased risk for which of the following long-term complications?
Q305
A 23-year-old man presents with fatigue and increased daytime somnolence. He says his symptoms began gradually 6 months ago and have progressively worsened and have begun to interfere with his job as a computer programmer. He is also bothered by episodes of paralysis upon waking from naps and reports visual hallucinations when falling asleep at night. He has been under the care of another physician for the past several months, who prescribed him the standard pharmacotherapy for his most likely diagnosis. However, he has continued to experience an incomplete remission of symptoms and has been advised against increasing the dose of his current medication because of an increased risk of adverse effects. Which of the following side effects is most closely associated with the standard drug treatment for this patient’s most likely diagnosis?
Q306
A pharmaceutical company is studying a new drug that inhibits the glucose transporter used by intestinal enterocytes to absorb glucose into the body. The drug was designed such that it would act upon the glucose transporter similarly to how cyanide acts upon cytochrome proteins. During pre-clinical studies, the behavior of this drug on the activity of the glucose transporter is examined. Specifically, enterocyte cells are treated with the drug and then glucose is added to the solution at a concentration that saturates the activity of the transporter. The transport velocity and affinity of the transporters under these conditions are then measured. Compared to the untreated state, which of the following changes would most likely be seen in these transporters after treatment?
Q307
A 65-year-old man is brought to the emergency department from his home. He is unresponsive. His son requested a wellness check because he had not heard from his father in 2 weeks. He reports that his father was sounding depressed during a telephone call. The paramedics found a suicide note and a half-empty bottle of antifreeze near the patient. The medical history includes hypertension and hyperlipidemia. The vital signs include: blood pressure 120/80 mm Hg, respiratory rate 25/min, heart rate 95/min, and temperature 37.0°C (98.5°F). He is admitted to the hospital. What do you expect the blood gas analysis to show?
Q308
A 24-year-old man presents to the postoperative unit after undergoing an appendectomy following 2 episodes of acute appendicitis. He complains of nausea and vomiting. On physical examination, his temperature is 36.9°C (98.4ºF), pulse rate is 96/minute, blood pressure is 122/80 mm Hg, and respiratory rate is 14/minute. His abdomen is soft on palpation, and bowel sounds are normoactive. Intravenous ondansetron is administered, and the patient reports relief from his symptoms. Which of the following best explains the mechanism of action of this drug?
Q309
A 57-year-old man presents for a regular check-up. He does not have any complaints at the time of presentation. He has a history of several episodes of acute non-necrotizing pancreatitis with the last episode being 2 years ago. Also, he was diagnosed with hypertension 5 years ago. Currently, he takes aspirin, atorvastatin, enalapril, and indapamide. He plays tennis twice a week, does low impact cardio workouts 3 times a week, and follows a low-fat diet. He smokes half a pack of cigarettes per day and refuses to quit smoking. The patient’s blood pressure is 140/85 mm Hg, heart rate is 88/min, respiratory rate is 14/min, and temperature is 36.6°C (97.9°F). His height is 181 cm (5 ft 11 in), weight is 99 kg (218 lb), and BMI is 30.8 kg/m2. Physical examination reveals multiple xanthomas on the patient’s trunk, elbows, and knees. Heart sounds are diminished with fixed splitting of S2 and an increased aortic component. The rest of the examination is unremarkable. The patient’s lipid profile shows the following results:
Total serum cholesterol 235.9 mg/dL
HDL 46.4 mg/dL
LDL 166.3 mg/dL
Triglycerides 600 mg/dL
Glucose 99 mg/dL
Which of the following modifications should be made to the patient’s therapy?
Q310
A 7-year-old boy is brought to the physician by his mother because his teachers have noticed him staring blankly on multiple occasions over the past month. These episodes last for several seconds and occasionally his eyelids flutter. He was born at term and has no history of serious illness. He has met all his developmental milestones. He appears healthy. Neurologic examination shows no focal findings. Hyperventilation for 30 seconds precipitates an episode of unresponsiveness and eyelid fluttering that lasts for 7 seconds. He regains consciousness immediately afterward. An electroencephalogram shows 3-Hz spikes and waves. Which of the following is the most appropriate pharmacotherapy for this patient?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 301: A 50-year-old woman presents to the clinic with joint pain that has persisted for the last 2 months. She reports having intermittently swollen, painful hands bilaterally. She adds that when she wakes up in the morning, her hands are stiff and do not loosen up until an hour later. The pain tends to improve with movement. Physical examination is significant for warm, swollen, tender proximal interphalangeal joints, metacarpophalangeal joints, and wrists bilaterally. Laboratory results are positive for rheumatoid factor (4-fold greater than the upper limit of normal (ULN)) and anti-cyclic citrullinated peptide (anti-CCP) antibodies (3-fold greater than ULN). CRP and ESR are elevated. Plain X-rays of the hand joints show periarticular osteopenia and bony erosions. She was started on the first-line drug for her condition which inhibits dihydrofolate reductase. Which medication was this patient started on?
A. Hydroxyurea
B. Allopurinol
C. Methotrexate (Correct Answer)
D. 5-fluorouracil
E. Leflunomide
Explanation: ***Methotrexate***
- The patient's clinical presentation (symmetrical polyarthritis, morning stiffness, elevated inflammatory markers, positive **rheumatoid factor**, and **anti-CCP antibodies**) is classic for **rheumatoid arthritis (RA)**.
- **Methotrexate** is the **first-line disease-modifying anti-rheumatic drug (DMARD)** for RA and acts by inhibiting **dihydrofolate reductase**, thereby interfering with purine and pyrimidine synthesis.
*Hydroxyurea*
- **Hydroxyurea** is an antineoplastic agent that works by inhibiting **ribonucleotide reductase**, not dihydrofolate reductase.
- It is primarily used in conditions like **myeloproliferative disorders** (e.g., chronic myeloid leukemia, polycythemia vera, essential thrombocythemia) and **sickle cell disease**, not rheumatoid arthritis.
*Allopurinol*
- **Allopurinol** is a **xanthine oxidase inhibitor** used to reduce **uric acid production** in conditions like **gout and tumor lysis syndrome**.
- It is not indicated for the treatment of rheumatoid arthritis, nor does it inhibit dihydrofolate reductase.
*5-fluorouracil*
- **5-fluorouracil** is a **pyrimidine analog** that inhibits **thymidylate synthase** (after being metabolized to 5-FdUMP), primarily used in **chemotherapy for various cancers**, especially gastrointestinal malignancies.
- It does not inhibit dihydrofolate reductase and is not used to treat rheumatoid arthritis.
*Leflunomide*
- **Leflunomide** is another DMARD used for rheumatoid arthritis, but it inhibits **dihydroorotate dehydrogenase**, an enzyme involved in *de novo pyrimidine synthesis*, not dihydrofolate reductase.
- While it is a treatment for RA, it is not the medication that acts specifically by inhibiting dihydrofolate reductase.
Question 302: A 78-year-old woman presents to the orthopedic department for an elective total left knee arthroplasty. She has had essential hypertension for 25 years and type 2 diabetes mellitus for 35 years. She has smoked 20–30 cigarettes per day for the past 40 years. The operation was uncomplicated. On day 3 post-surgery, she complains of left leg pain and swelling. On examination, her left leg appears red and edematous, and there are dilated superficial veins on the left foot. Using Wells’ criteria, the patient is diagnosed with a provoked deep venous thrombosis. Which of the following is the best initial therapy for this patient?
A. Oral apixaban monotherapy (Correct Answer)
B. Inferior vena cava (IVC) filter
C. Oral dabigatran monotherapy
D. Complete bed rest
E. Long-term aspirin
Explanation: ***Oral apixaban monotherapy***
- **Apixaban** is a **direct oral anticoagulant** (DOAC) that offers effective and convenient treatment for DVT, particularly in postoperative settings.
- Its fixed-dose regimen, favorable safety profile (especially regarding bleeding risk), and lack of need for routine monitoring make it a preferred initial therapy for most patients with DVT.
*Inferior vena cava (IVC) filter*
- **IVC filters** are generally reserved for patients with contraindications to anticoagulation or those who experience recurrent PEs despite adequate anticoagulation.
- They do not treat the DVT itself but rather aim to prevent pulmonary emboli, and their use is associated with potential complications.
*Oral dabigatran monotherapy*
- **Dabigatran** is another direct oral anticoagulant, but its initial DVT treatment typically involves a 5-10 day bridging period with a parenteral anticoagulant (e.g., LMWH) before starting oral therapy.
- Unlike apixaban, it is not recommended as monotherapy for initial DVT treatment.
*Complete bed rest*
- **Complete bed rest** is not recommended for DVT as it can contribute to **venous stasis** and potentially worsen outcomes.
- Early ambulation, once anticoagulation is initiated, is encouraged to reduce pain and swelling and promote recovery.
*Long-term aspirin*
- **Aspirin** has a role in secondary prevention of recurrent DVT/PE in some patients after initial anticoagulant therapy.
- It is not sufficient as a primary or initial treatment for an acute DVT, as its antithrombotic effects are much weaker compared to DOACs or other anticoagulants.
Question 303: A 36-year-old man comes to the physician because of increasing back pain for the past 6 months. The pain is worse when he wakes up and improves throughout the day. He has problems bending forward. He has taken ibuprofen which resulted in limited relief. His only medication is a topical corticosteroid for two erythematous, itchy patches of the skin. His mother has rheumatoid arthritis. His temperature is 37.1°C (98.8°F), pulse is 75/min, respirations are 14/min, and blood pressure is 126/82 mmHg. Examination shows a limited spinal flexion. He has two patches with erythematous papules on his right forearm. He has tenderness on percussion of his sacroiliac joints. An x-ray of his spine is shown. Which of the following is most likely to improve mobility in this patient?
A. Rituximab
B. Etanercept (Correct Answer)
C. Leflunomide
D. Methotrexate
E. Prednisolone
Explanation: ***Etanercept***
- The patient's symptoms (back pain and stiffness improving throughout the day, limited spinal flexion, sacroiliac joint tenderness, erythematous skin patches) along with the X-ray showing **vertebral syndesmophytes**, are highly suggestive of **ankylosing spondylitis with concurrent psoriasis (psoriatic spondyloarthritis)**.
- **Etanercept** is a **TNF-alpha inhibitor**, which is a highly effective biologic agent for treating both ankylosing spondylitis and psoriatic arthritis, improving spinal mobility and skin symptoms.
*Rituximab*
- **Rituximab** is an anti-CD20 monoclonal antibody primarily used in **rheumatoid arthritis** and certain lymphomas.
- It is generally **not effective** for axial spondyloarthritis or psoriatic arthritis.
*Leflunomide*
- **Leflunomide** is a **DMARD** used for **rheumatoid arthritis** and sometimes **psoriatic arthritis**, but it has limited efficacy in treating **axial disease** (spinal involvement) in spondyloarthritis and is not a first-line treatment for improving mobility in this context.
- Its mechanism of action involves inhibiting pyrimidine synthesis and is not as potent for spinal inflammation as TNF-alpha inhibitors.
*Methotrexate*
- **Methotrexate** is a common **DMARD** used for **rheumatoid arthritis** and **peripheral psoriatic arthritis**, as well as psoriasis.
- However, it has **limited efficacy** in treating the **axial symptoms** (spinal involvement) of ankylosing spondylitis or psoriatic spondyloarthritis.
*Prednisolone*
- **Prednisolone** (a corticosteroid) can provide short-term symptomatic relief for inflammatory conditions but is **not a long-term solution** for spondyloarthritis due to significant side effects.
- It does not significantly alter the disease course or achieve sustained improvement in mobility for this condition compared to biologics.
Question 304: A previously healthy 46-year-old woman comes to the physician because of a 3-month history of fatigue and progressive shortness of breath. She does not take any medications. Her pulse is 93/min and blood pressure is 112/80 mm Hg. Examination shows no abnormalities. Her hemoglobin concentration is 8 g/dL, leukocyte count is 22,000/mm3, and platelet count is 80,000/mm3. A peripheral blood smear shows increased numbers of circulating myeloblasts. Bone marrow biopsy confirms the diagnosis of acute myeloid leukemia. ECG, x-ray of the chest, and echocardiogram show no abnormalities. The patient is scheduled to start induction chemotherapy with cytarabine and daunorubicin. This patient is at increased risk for which of the following long-term complications?
A. Left ventricular dysfunction (Correct Answer)
B. Gross hematuria
C. Bilateral tinnitus
D. Endometrial hyperplasia
E. Decreased diffusing capacity of the lung for carbon monoxide
Explanation: ***Left ventricular dysfunction***
- **Daunorubicin** is an **anthracycline antibiotic** frequently used in AML chemotherapy; it is known to cause **dose-dependent cardiotoxicity**, leading to **left ventricular dysfunction** and congestive heart failure.
- The risk of cardiotoxicity is cumulative and can manifest years after treatment, making it a significant long-term complication.
*Gross hematuria*
- **Gross hematuria** is typically associated with hemorrhagic cystitis, a common side effect of **cyclophosphamide** or **ifosfamide** due to their metabolite **acrolein**.
- These agents are not part of the standard induction regimen mentioned (cytarabine and daunorubicin) for AML, thus making this complication less likely in this specific context.
*Bilateral tinnitus*
- **Bilateral tinnitus** is a common adverse effect of **cisplatin** and other **platinum-based chemotherapy agents**, which cause ototoxicity.
- These drugs are not part of the standard induction chemotherapy for AML described in the scenario.
*Endometrial hyperplasia*
- **Endometrial hyperplasia** is primarily associated with **unopposed estrogen stimulation** and is not a direct long-term complication of cytarabine and daunorubicin chemotherapy.
- While some chemotherapy can induce premature menopause, endometrial hyperplasia is not a specific or common drug-related long-term complication of this AML regimen.
*Decreased diffusing capacity of the lung for carbon dioxide*
- A **decreased diffusing capacity of the lung for carbon monoxide (DLCO)** is typically associated with **bleomycin-induced pulmonary fibrosis** or other interstitial lung diseases.
- **Bleomycin** is not used in the standard AML induction regimen of cytarabine and daunorubicin, making this an unlikely long-term complication in this patient.
Question 305: A 23-year-old man presents with fatigue and increased daytime somnolence. He says his symptoms began gradually 6 months ago and have progressively worsened and have begun to interfere with his job as a computer programmer. He is also bothered by episodes of paralysis upon waking from naps and reports visual hallucinations when falling asleep at night. He has been under the care of another physician for the past several months, who prescribed him the standard pharmacotherapy for his most likely diagnosis. However, he has continued to experience an incomplete remission of symptoms and has been advised against increasing the dose of his current medication because of an increased risk of adverse effects. Which of the following side effects is most closely associated with the standard drug treatment for this patient’s most likely diagnosis?
A. Weight gain and metabolic syndrome
B. Nephrogenic diabetes insipidus
C. Parkinsonism and tardive dyskinesia
D. Loss of concentration, memory impairment
E. Cardiac irregularities, nervousness, hallucinations (Correct Answer)
Explanation: ***Cardiac irregularities, nervousness, hallucinations***
- The patient's symptoms (fatigue, excessive daytime somnolence, sleep paralysis, and hypnagogic hallucinations) are classic for **narcolepsy**.
- The standard pharmacotherapy for narcolepsy often includes **stimulants** (e.g., modafinil, armodafinil, methylphenidate, amphetamines), which can cause side effects like **cardiac irregularities** (tachycardia, arrhythmias), **nervousness/anxiety**, and in some cases, exacerbation of **hallucinations** or psychosis.
*Weight gain and metabolic syndrome*
- This side effect is primarily associated with **second-generation antipsychotics**, which are not the first-line treatment for narcolepsy.
- While some medications can cause weight changes, it is not the most typical or limiting side effect for narcolepsy stimulants as implied by the clinical context.
*Nephrogenic diabetes insipidus*
- This is a well-known side effect of **lithium**, a mood stabilizer used in bipolar disorder, which is not indicated for narcolepsy.
- There is no direct link between narcolepsy treatment and nephrogenic diabetes insipidus.
*Parkinsonism and tardive dyskinesia*
- These are **extrapyramidal side effects** primarily associated with **first-generation antipsychotics** and, less commonly, some second-generation antipsychotics or antiemetics.
- These are not typical side effects of the stimulant medications used to treat narcolepsy.
*Loss of concentration, memory impairment*
- While some conditions can cause cognitive side effects, the **stimulants** used for narcolepsy are generally intended to **improve concentration and alertness**, not impair them.
- If these side effects were to occur, they would be atypical or paradoxical reactions to standard treatment.
Question 306: A pharmaceutical company is studying a new drug that inhibits the glucose transporter used by intestinal enterocytes to absorb glucose into the body. The drug was designed such that it would act upon the glucose transporter similarly to how cyanide acts upon cytochrome proteins. During pre-clinical studies, the behavior of this drug on the activity of the glucose transporter is examined. Specifically, enterocyte cells are treated with the drug and then glucose is added to the solution at a concentration that saturates the activity of the transporter. The transport velocity and affinity of the transporters under these conditions are then measured. Compared to the untreated state, which of the following changes would most likely be seen in these transporters after treatment?
A. Unchanged Km and decreased Vmax (Correct Answer)
B. Unchanged Km and unchanged Vmax
C. Increased Km and unchanged Vmax
D. Increased Km and decreased Vmax
E. Decreased Km and decreased Vmax
Explanation: ***Unchanged Km and decreased Vmax***
- The drug functions similarly to **cyanide**, which works as a **noncompetitive inhibitor** by binding irreversibly to a site other than the active site
- **Noncompetitive inhibition** results in a **decreased Vmax** (maximum transport velocity) because fewer active transporters are available, but the **Km (substrate affinity) remains unchanged** as the binding affinity of the remaining active transporters is unaffected
- This is the expected pattern when glucose is added at saturating concentrations in the presence of an irreversible noncompetitive inhibitor
*Unchanged Km and unchanged Vmax*
- This would imply no significant effect of the drug on the glucose transporter, which contradicts the drug's design as an inhibitor
- An unaffected Vmax suggests that the maximum transport rate is maintained, and an unchanged Km indicates unaltered affinity—neither of which aligns with the action of a noncompetitive inhibitor
*Increased Km and unchanged Vmax*
- An **increased Km** signifies a **decreased affinity** of the transporter for glucose, which is characteristic of **competitive inhibition**
- An **unchanged Vmax** means the maximum transport rate is still achievable at high substrate concentrations, as competitive inhibitors can be overcome by saturating substrate concentrations
- This pattern does not match the cyanide-like irreversible noncompetitive inhibitor described
*Increased Km and decreased Vmax*
- This pattern suggests **mixed inhibition** or **uncompetitive inhibition**, where both Km and Vmax are affected
- While Vmax is appropriately decreased, the increase in Km indicates reduced affinity, which is not the primary mechanism for a cyanide-like noncompetitive inhibitor that binds irreversibly to a separate site
*Decreased Km and decreased Vmax*
- A **decreased Km** would imply an **increased affinity** of the transporter for glucose, which is not expected from an inhibitor designed to reduce overall transport
- Although Vmax is appropriately decreased, the change in Km does not fit the typical profile of a noncompetitive inhibitor acting in a cyanide-like manner
Question 307: A 65-year-old man is brought to the emergency department from his home. He is unresponsive. His son requested a wellness check because he had not heard from his father in 2 weeks. He reports that his father was sounding depressed during a telephone call. The paramedics found a suicide note and a half-empty bottle of antifreeze near the patient. The medical history includes hypertension and hyperlipidemia. The vital signs include: blood pressure 120/80 mm Hg, respiratory rate 25/min, heart rate 95/min, and temperature 37.0°C (98.5°F). He is admitted to the hospital. What do you expect the blood gas analysis to show?
A. Non-anion gap metabolic acidosis
B. Metabolic alkalosis
C. Respiratory acidosis
D. Anion gap metabolic acidosis (Correct Answer)
E. Mixed acid-base disorder
Explanation: ***Anion gap metabolic acidosis***
- The patient's history of **antifreeze ingestion** indicates likely exposure to **ethylene glycol**, which is metabolized into toxic acids (glycolic and oxalic acid).
- These accumulating acids lead to an **increased anion gap metabolic acidosis**.
*Non-anion gap metabolic acidosis*
- This type of acidosis typically results from **bicarbonate loss** (e.g., severe diarrhea) or **excessive chloride intake**, which is not indicated by the antifreeze ingestion.
- It involves a normal anion gap because other unmeasured anions do not accumulate.
*Metabolic alkalosis*
- This imbalance is characterized by an **increase in bicarbonate** or a significant loss of acid, often due to vomiting or diuretic use.
- Antifreeze poisoning directly leads to acid accumulation, precisely the opposite of metabolic alkalosis.
*Respiratory acidosis*
- This occurs due to **hypoventilation** and subsequent buildup of CO2, leading to increased carbonic acid.
- While respiratory rate is elevated, the primary problem here is metabolic due to toxin ingestion, not respiratory CO2 retention.
*Mixed acid-base disorder*
- While a mixed disorder is possible in complex cases, the presentation with antifreeze poisoning is classically dominated by a **severe anion gap metabolic acidosis**.
- There is no clear indication of a separate primary respiratory or alkalotic disorder at onset to warrant a "mixed" label as the primary anticipated finding.
Question 308: A 24-year-old man presents to the postoperative unit after undergoing an appendectomy following 2 episodes of acute appendicitis. He complains of nausea and vomiting. On physical examination, his temperature is 36.9°C (98.4ºF), pulse rate is 96/minute, blood pressure is 122/80 mm Hg, and respiratory rate is 14/minute. His abdomen is soft on palpation, and bowel sounds are normoactive. Intravenous ondansetron is administered, and the patient reports relief from his symptoms. Which of the following best explains the mechanism of action of this drug?
A. Inhibition of serotonin receptors on the vagal and spinal afferent nerves from the intestines (Correct Answer)
B. Inhibition of dopamine receptors on chemoreceptor trigger zone (CTZ)
C. Inhibition of gastroesophageal motility
D. Stimulation of 5-HT3 receptors on the nucleus of the tractus solitarius
E. Stimulation of intestinal and colonic motility
Explanation: ***Inhibition of serotonin receptors on the vagal and spinal afferent nerves from the intestines***
- **Ondansetron** is a **5-HT3 receptor antagonist** that primarily acts by blocking serotonin receptors located on the **vagal and spinal afferent nerves** in the gastrointestinal tract.
- By blocking these receptors, it prevents the transmission of **emetic signals** from the gut to the brainstem's vomiting center, effectively reducing nausea and vomiting.
*Inhibition of dopamine receptors on chemoreceptor trigger zone (CTZ)*
- This is the mechanism of action for **dopamine antagonists**, such as **metoclopramide** or **prochlorperazine**, which are also antiemetics but work differently from ondansetron.
- The CTZ is located outside the blood-brain barrier and is sensitive to blood-borne toxins and drugs, but its primary pathway for signaling to the vomiting center is blocked by dopamine antagonists.
*Inhibition of gastroesophageal motility*
- This mechanism is not typically associated with antiemetics like ondansetron, which generally do not significantly affect gastroesophageal motility.
- Inhibiting motility can sometimes worsen symptoms of nausea or lead to delayed gastric emptying, which is not the therapeutic goal of ondansetron.
*Stimulation of 5-HT3 receptors on the nucleus of the tractus solitarius*
- Ondansetron is an **antagonist** (inhibitor), not a stimulator, of 5-HT3 receptors.
- Stimulation of 5-HT3 receptors on the nucleus of the tractus solitarius would likely *promote* nausea and vomiting, the opposite of ondansetron's effect.
*Stimulation of intestinal and colonic motility*
- Drugs that stimulate intestinal and colonic motility are typically **prokinetics**, like **metoclopramide** (which also has antiemetic properties via dopamine receptor antagonism), but this is not the primary mechanism of ondansetron.
- Ondansetron's action is focused on blocking serotonin receptors to prevent nausea and vomiting, not directly on stimulating gut motility.
Question 309: A 57-year-old man presents for a regular check-up. He does not have any complaints at the time of presentation. He has a history of several episodes of acute non-necrotizing pancreatitis with the last episode being 2 years ago. Also, he was diagnosed with hypertension 5 years ago. Currently, he takes aspirin, atorvastatin, enalapril, and indapamide. He plays tennis twice a week, does low impact cardio workouts 3 times a week, and follows a low-fat diet. He smokes half a pack of cigarettes per day and refuses to quit smoking. The patient’s blood pressure is 140/85 mm Hg, heart rate is 88/min, respiratory rate is 14/min, and temperature is 36.6°C (97.9°F). His height is 181 cm (5 ft 11 in), weight is 99 kg (218 lb), and BMI is 30.8 kg/m2. Physical examination reveals multiple xanthomas on the patient’s trunk, elbows, and knees. Heart sounds are diminished with fixed splitting of S2 and an increased aortic component. The rest of the examination is unremarkable. The patient’s lipid profile shows the following results:
Total serum cholesterol 235.9 mg/dL
HDL 46.4 mg/dL
LDL 166.3 mg/dL
Triglycerides 600 mg/dL
Glucose 99 mg/dL
Which of the following modifications should be made to the patient’s therapy?
A. Add aprotinin
B. Add simvastatin
C. Add metformin
D. Add fenofibrate (Correct Answer)
E. Increase atorvastatin dosage
Explanation: ***Add fenofibrate***
- The patient presents with significantly elevated **triglycerides (600 mg/dL)**, multiple episodes of **acute non-necrotizing pancreatitis**, and **eruptive xanthomas**, which are all indicative of severe hypertriglyceridemia.
- **Fibrates, such as fenofibrate**, are the most effective class of drugs for lowering very high triglyceride levels and reducing the risk of pancreatitis.
*Add aprotinin*
- **Aprotinin** is an antifibrinolytic agent that is no longer used due to safety concerns and is not indicated for the management of hypertriglyceridemia or pancreatitis prevention.
- Its primary use was in reducing blood loss during complex surgeries, specifically cardiac surgery.
*Add simvastatin*
- **Simvastatin** is a statin, and while statins are effective in reducing LDL cholesterol, they have a limited effect on significantly elevated triglycerides.
- The patient is already on atorvastatin, and adding a second statin would not be the primary approach for managing severe hypertriglyceridemia, nor would it provide substantial additional triglyceride-lowering effects compared to a fibrate.
*Add metformin*
- **Metformin** is an oral antihyperglycemic agent used to treat type 2 diabetes by improving insulin sensitivity and reducing hepatic glucose production.
- The patient's **glucose level is normal (99 mg/dL)**, and there is no indication of diabetes or pre-diabetes, making metformin inappropriate.
*Increase atorvastatin dosage*
- While atorvastatin can lower triglycerides to some extent, it is primarily used for LDL-C reduction. Increasing the dosage would not be as effective as a fibrate in addressing the severe **hypertriglyceridemia (600 mg/dL)** and the associated risk of pancreatitis.
- The most significant concern for this patient is the high triglyceride level and the history of pancreatitis, which requires a more targeted therapy beyond increased statin dosage.
Question 310: A 7-year-old boy is brought to the physician by his mother because his teachers have noticed him staring blankly on multiple occasions over the past month. These episodes last for several seconds and occasionally his eyelids flutter. He was born at term and has no history of serious illness. He has met all his developmental milestones. He appears healthy. Neurologic examination shows no focal findings. Hyperventilation for 30 seconds precipitates an episode of unresponsiveness and eyelid fluttering that lasts for 7 seconds. He regains consciousness immediately afterward. An electroencephalogram shows 3-Hz spikes and waves. Which of the following is the most appropriate pharmacotherapy for this patient?
A. Phenytoin
B. Clonazepam
C. Levetiracetam
D. Carbamazepine
E. Ethosuximide (Correct Answer)
Explanation: ***Ethosuximide***
- This patient presents with classic features of **absence seizures**, including brief staring spells with eyelid fluttering, precipitation by hyperventilation, and a characteristic **3-Hz spike-and-wave pattern on EEG**. **Ethosuximide** is the first-line pharmacotherapy for typical absence seizures due to its high efficacy and favorable side effect profile.
- It works by blocking **T-type calcium channels** in the thalamic neurons, which are crucial in generating the 3-Hz spike-and-wave discharges characteristic of absence seizures.
*Phenytoin*
- **Phenytoin** is a broad-spectrum anticonvulsant primarily used for **tonic-clonic seizures** and **focal seizures**.
- It is generally **ineffective** and can sometimes exacerbate absence seizures, making it an inappropriate choice for this patient.
*Clonazepam*
- **Clonazepam** is a benzodiazepine that can be used as an adjunct in some epilepsy syndromes, particularly for myoclonic or atypical absence seizures.
- While it has broad anti-seizure properties, it is not the **first-line drug of choice** for typical absence seizures, and its use is often limited by sedative side effects and the potential for tolerance and dependence.
*Levetiracetam*
- **Levetiracetam** is a broad-spectrum antiepileptic drug effective for focal, generalized tonic-clonic, and myoclonic seizures.
- While it can be used for absence seizures, **ethosuximide** or valproic acid are generally considered more effective as monotherapy options for typical absence seizures due to their specific mechanism of action.
*Carbamazepine*
- **Carbamazepine** is primarily used for **focal seizures** and **tonic-clonic seizures**.
- Like phenytoin, **carbamazepine** is known to **exacerbate absence seizures**, making it an unsuitable and potentially harmful treatment choice for this patient.